15 Nov 2019, 07:13 GMT+10
SAN CLEMENTE, CA / ACCESSWIRE / November 14, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months ended September 30, 2019.
Recent Highlights and Accomplishments
'Our strong third quarter progress demonstrates the increasing resurgence of LAP-BAND and our organizational commitment to the market, physicians and patients,' said Bart Bandy, President and Chief Executive Officer at ReShape Lifesciences. 'We are confident that through our demonstrated focus on this continuously evolving industry we can continue to deliver increased value as a leading obesity solution company.'
Third Quarter 2019 Financial Results
Revenue for the three months ended September 30, 2019, was $3.5 million compared to $4.4 million in revenues for the three months ended June 30, 2019.
Gross profit for the third quarter of 2019 was $2.1 million compared to $2.9 million for the three months ended June 30, 2019.
Selling, general and administrative expenses for the three months ended September 30, 2019 were $5.4 million compared to $6.8 million for the three months ended June 30, 2019.
Research and development expenses were $0.9 million for the third quarter of 2019 compared to $1.0 million for the three months ended June 30, 2019.
The Company recognized a contingent loss of $1.5 million relating to a patent infringement claim with Fulfillium who agreed to dismiss with prejudice the previously disclosed lawsuits filed on their behalf.
As of September 30, 2019, the Company had cash and cash equivalents totaling $7.7 million.
Management will host an investment community conference call today beginning at 1:30 p.m. Pacific Time 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing (877) 280-7473 for domestic callers or (707) 287-9370 for international callers, using Conference ID: 1679507. To listen to a live webcast or a replay, please visit the investor relations section of the Company website at: http://ir.reshapelifesciences.com/.
About ReShape Lifesciences Inc.
ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as 'expect,' 'plan,' 'anticipate,' 'could,' 'may,' 'intend,' 'will,' 'continue,' 'future,' other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of the LAP-BAND system; our ability to continue as a going concern if we are unable to improve our operating results or obtain additional financing; risks related to ownership of our securities as a result of our delisting from the Nasdaq Capital Market; our proposed ReShape Vest product may not be successfully developed and commercialized; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system and LAP-BAND system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as 'risk factors' in our annual report on Form 10-K filed May 16, 2019 and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
RESHAPE LIFESCIENCES INC.
Condensed Consolidated Balance Sheets
(dollars in thousands, except per share amounts; unaudited)
|September 30,||December 31,|
Cash and cash equivalents
Accounts and other receivables (net of allowance for bad debts of $558 at September 30, 2019 and $236 at December 31, 2018)
Finished goods inventory
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Other intangible assets, net
LIABILITIES AND STOCKHOLDERS' EQUITY
Accrued and other liabilities
Asset purchase consideration payable, current
Operating lease liabilities, current
Total current liabilities
Asset purchase consideration payable, noncurrent
Operating lease liabilities, noncurrent
Deferred income taxes
Common stock warrant liability
Stockholders' (deficit) equity:
Preferred stock, 5,000,000 shares authorized:
Series B convertible preferred stock, $0.01 par value; 3 and 159 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively
Series C convertible preferred stock, $0.01 par value; 95,388 shares issued and outstanding at September 30, 2019 and December 31, 2018
Common stock, $0.001 par value; 275,000,000 shares authorized at September 30, 2019 and December 31, 2018; 353,794 and 73,092 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Total stockholders' (deficit) equity
Total liabilities and stockholder' equity
RESHAPE LIFESCIENCES INC.
Condensed Consolidated Statements of Operations
(dollars in thousands, except per share amounts; unaudited)
|Three Months Ended|
Nine Months Ended
Cost of revenue
Selling, general and administrative
Research and development
Impairment of intangible assets
Total operating expenses
Other expense (income), net:
Interest expense, net
Loss on extinguishment of debt
(Gain) loss on foreign currency transactions
Loss from continuing operations before income taxes
Income tax benefit
Watch latest videos
Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Thunder in Miami
Despite unrelenting pressures from passenger rights advocates, intense media scrutiny and strident demands from passengers, airlines have remained largely immutable ...
SYDNEY, Australia - Stocks were mixed in Asia on Tuesday.China's big run on Monday sapped its market, however the Shanghai ...
Ampere Vehicles is acquiring Noida based E-3Wheeler company, Bestway Agencies Pvt. Ltd. (BAPL), which sells e-Rickshaws under the ELE brand. ...
One of the lessons the current coronavirus pandemic has taught us is that we depend on electronic devices more than ...
PARIS, France - Although crude prices have rebounded from coronavirus crisis lows, oil executives and experts are starting to ask ...
Budget breaks President Ramaphosa's promise - economists' letter to MPsPressures in some departments, including those previously earmarked for budget reductions ...
As coronavirus cases around the world approach 11.5 million, governments are struggling with how to reopen their economies, leading some ...
A new Gallup poll showed Monday that 38% of Americans approve of President Donald Trump's White House performance, a figure ...
A U.S. federal judge ruled Monday that a controversial pipeline that runs through Native American lands in North Dakota be ...
CAMP SIONGCO, Maguindanao, Philippines - Troops of the 37th Infantry Battalion, under 603rd Infantry Brigade, foiled a communist NPA (CNT) ...
JERUSALEM - As scandal-plagued Prime Minister Benjamin Netanyahu stands trial for corruption, his 28-year-old son has emerged as a driving ...
WASHINGTON, DC - Broadway actor Nick Cordero, aged 41, has passed away after a long battle with coronavirus.According to Variety, ...